{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:47:37Z","timestamp":1791114457725,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"49","license":[{"start":{"date-parts":[[2013,6,17]],"date-time":"2013-06-17T00:00:00Z","timestamp":1371427200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1038\/onc.2013.217","type":"journal-article","created":{"date-parts":[[2013,6,17]],"date-time":"2013-06-17T11:23:59Z","timestamp":1371468239000},"page":"5512-5521","source":"Crossref","is-referenced-by-count":72,"title":["PPAR\u03b3 maintains ERBB2-positive breast cancer stem cells"],"prefix":"10.1038","volume":"32","author":[{"given":"X","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D S","family":"Conklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,17]]},"reference":[{"issue":"Suppl 2","key":"BFonc2013217_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000055404","volume":"61","author":"S Menard","year":"2001","unstructured":"Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A . HER2 as a prognostic factor in breast cancer. Oncology 2001; 61 (Suppl 2): 67\u201372.","journal-title":"Oncology"},{"key":"BFonc2013217_CR2","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al. Efficacy and safety of trastuzumab as a single agent in first-line treatmentof HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719\u2013726.","journal-title":"J Clin Oncol"},{"key":"BFonc2013217_CR3","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645\u2013648.","journal-title":"Nature"},{"key":"BFonc2013217_CR4","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983\u20133988.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2013217_CR5","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/nrc1212","volume":"3","author":"M Smalley","year":"2003","unstructured":"Smalley M, Ashworth A . Stem cells and breast cancer: a field in transit. Nat Rev Cancer 2003; 3: 832\u2013844.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2013217_CR6","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","volume":"444","author":"S Bao","year":"2006","unstructured":"Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756\u2013760.","journal-title":"Nature"},{"key":"BFonc2013217_CR7","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/jnci\/djn123","volume":"100","author":"X Li","year":"2008","unstructured":"Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672\u2013679.","journal-title":"J Natl Cancer Inst"},{"key":"BFonc2013217_CR8","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1200\/JCO.2007.15.1829","volume":"26","author":"CE Eyler","year":"2008","unstructured":"Eyler CE, Rich JN . Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008; 26: 2839\u20132845.","journal-title":"J Clin Oncol"},{"key":"BFonc2013217_CR9","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/jnci\/djj505","volume":"98","author":"M Diehn","year":"2006","unstructured":"Diehn M, Clarke MF . Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 2006; 98: 1755\u20131757.","journal-title":"J Natl Cancer Inst"},{"key":"BFonc2013217_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10911-009-9116-x","volume":"14","author":"PL Bedard","year":"2009","unstructured":"Bedard PL, Cardoso F, Piccart-Gebhart MJ . Stemming resistance to HER-2 targeted therapy. J Mammary Gland Biol Neoplasia 2009; 14: 55\u201366.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"BFonc2013217_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bbrc.2010.05.041","volume":"397","author":"C Oliveras-Ferraros","year":"2010","unstructured":"Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Cufi S, Del Barco S, Lopez-Bonet E et al. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg\/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistanceto trastuzumab (Herceptin). Biochem Biophys Res Commun 2010; 397: 27\u201333.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFonc2013217_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2217\/pgs.10.194","volume":"12","author":"D Fumagalli","year":"2011","unstructured":"Fumagalli D, Michiels S, Sotiriou C . CD44+ CD24-\/low phenotype and resistance to trastuzumab in HER2-positive breast cancer cell lines. Pharmacogenomics 2011; 12: 12\u201313.","journal-title":"Pharmacogenomics"},{"key":"BFonc2013217_CR13","doi-asserted-by":"crossref","unstructured":"Baumann J, Karch C, Kourtidis A, Conklin DS . The electronics of HER2\/neu positive breast cancer cells. Breast Cancer Recent Adv Biol Imaging Ther 2012. 17\u201336.","DOI":"10.5772\/22820"},{"key":"BFonc2013217_CR14","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-09-1550","volume":"70","author":"A Kourtidis","year":"2010","unstructured":"Kourtidis A, Jain R, Carkner RD, Eifert C, Brosnan MJ, Conklin DS . An RNA interference screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature. Cancer Res 2010; 70: 1783\u20131792.","journal-title":"Cancer Res"},{"key":"BFonc2013217_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ccr.2006.10.009","volume":"10","author":"K Chin","year":"2006","unstructured":"Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006; 10: 529\u2013541.","journal-title":"Cancer Cell"},{"key":"BFonc2013217_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1677\/erc.1.01147","volume":"13","author":"P Kauraniemi","year":"2006","unstructured":"Kauraniemi P, Kallioniemi A . Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer 2006; 13: 39\u201349.","journal-title":"Endocr Relat Cancer"},{"key":"BFonc2013217_CR17","first-page":"2194","volume":"63","author":"MA Dressman","year":"2003","unstructured":"Dressman MA, Baras A, Malinowski R, Alvis LB, Kwon I, Walz TM et al. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. Cancer Res 2003; 63: 2194\u20132199.","journal-title":"Cancer Res"},{"key":"BFonc2013217_CR18","doi-asserted-by":"publisher","first-page":"10848","DOI":"10.1073\/pnas.96.19.10848","volume":"96","author":"Y Zhu","year":"1999","unstructured":"Zhu Y, Qi C, Jain S, Le Beau MM, Espinosa R 3rd, Atkins GB et al. Amplificationand overexpression of peroxisome proliferator-activated receptor binding protein (PBP\/PPARBP) gene in breast cancer. Proc Natl Acad Sci USA 1999; 96: 10848\u201310853.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2013217_CR19","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1038\/sj.onc.1207361","volume":"23","author":"F Bertucci","year":"2004","unstructured":"Bertucci F, Borie N, Ginestier C, Groulet A, Charafe-Jauffret E, Adelaide J et al. Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene 2004; 23: 2564\u20132575.","journal-title":"Oncogene"},{"key":"BFonc2013217_CR20","doi-asserted-by":"publisher","first-page":"R16","DOI":"10.1186\/bcr2240","volume":"11","author":"A Kourtidis","year":"2009","unstructured":"Kourtidis A, Srinivasaiah R, Carkner RD, Brosnan MJ, Conklin DS . Peroxisome proliferator-activated receptor-gamma protects ERBB2-positive breast cancer cells from palmitate toxicity. Breast Cancer Res 2009; 11: R16.","journal-title":"Breast Cancer Res"},{"key":"BFonc2013217_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nm1025","volume":"10","author":"RM Evans","year":"2004","unstructured":"Evans RM, Barish GD, Wang YX . PPARs and the complex journey to obesity. Nat Med 2004; 10: 355\u2013361.","journal-title":"Nat Med"},{"key":"BFonc2013217_CR22","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.cell.2005.11.026","volume":"123","author":"M Lehrke","year":"2005","unstructured":"Lehrke M, Lazar MA . The many faces of PPARgamma. Cell 2005; 123: 993\u2013999.","journal-title":"Cell"},{"key":"BFonc2013217_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nrc1254","volume":"4","author":"L Michalik","year":"2004","unstructured":"Michalik L, Desvergne B, Wahli W . Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 2004; 4: 61\u201370.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2013217_CR24","doi-asserted-by":"publisher","first-page":"247379","DOI":"10.1155\/2008\/247379","volume":"2008","author":"RI Glazer","year":"2008","unstructured":"Glazer RI, Yuan H, Xie Z, Yin Y . PPARgamma and PPARdelta as modulators of neoplasia and cell fate. PPAR Res 2008; 2008: 247379.","journal-title":"PPAR Res"},{"key":"BFonc2013217_CR25","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1242\/jcs.114.22.4117","volume":"114","author":"M Pignatelli","year":"2001","unstructured":"Pignatelli M, Cortes-Canteli M, Lai C, Santos A, Perez-Castillo A . The peroxisome proliferator-activated receptor gamma is an inhibitor of ErbBs activity in human breast cancer cells. J Cell Sci 2001; 114: 4117\u20134126.","journal-title":"J Cell Sci"},{"key":"BFonc2013217_CR26","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.bcp.2006.05.009","volume":"72","author":"KY Kim","year":"2006","unstructured":"Kim KY, Kim SS, Cheon HG . Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells. Biochem Pharmacol 2006; 72: 530\u2013540.","journal-title":"Biochem Pharmacol"},{"key":"BFonc2013217_CR27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1097-2765(00)80047-7","volume":"1","author":"E Mueller","year":"1998","unstructured":"Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998; 1: 465\u2013470.","journal-title":"Mol Cell"},{"key":"BFonc2013217_CR28","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1006\/bbrc.2001.5491","volume":"286","author":"F Yin","year":"2001","unstructured":"Yin F, Wakino S, Liu Z, Kim S, Hsueh WA, Collins AR et al. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Comm 2001; 286: 916\u2013922.","journal-title":"Biochem Biophys Res Comm"},{"key":"BFonc2013217_CR29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1023\/A:1016114026769","volume":"74","author":"E Elstner","year":"2002","unstructured":"Elstner E, Williamson EA, Zang C, Fritz J, Heber D, Fenner M et al. Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat 2002; 74: 155\u2013165.","journal-title":"Breast Cancer Res Treat"},{"key":"BFonc2013217_CR30","first-page":"3198","volume":"9","author":"Z Yang","year":"2003","unstructured":"Yang Z, Bagheri-Yarmand R, Balasenthil S, Hortobagyi G, Sahin AA, Barnes CJ et al. HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy. Clin Cancer Res 2003; 9: 3198\u20133203.","journal-title":"Clin Cancer Res"},{"key":"BFonc2013217_CR31","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/annonc\/mdr534","volume":"23","author":"X He","year":"2012","unstructured":"He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC . Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol 2012; 23: 1771\u20131780.","journal-title":"Ann Oncol"},{"key":"BFonc2013217_CR32","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1038\/sj.bjc.6604786","volume":"99","author":"W Chearwae","year":"2008","unstructured":"Chearwae W, Bright JJ . PPARgamma agonists inhibit growth and expansion of CD133+ brain tumour stem cells. Br J Cancer 2008; 99: 2044\u20132053.","journal-title":"Br J Cancer"},{"key":"BFonc2013217_CR33","doi-asserted-by":"publisher","first-page":"4949","DOI":"10.1158\/0008-5472.CAN-09-1962","volume":"70","author":"T Tsao","year":"2010","unstructured":"Tsao T, Kornblau S, Safe S, Watt JC, Ruvolo V, Chen W et al. Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia. Cancer Res 2010; 70: 4949\u20134960.","journal-title":"Cancer Res"},{"key":"BFonc2013217_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1182\/blood-2011-06-363093","volume":"119","author":"L Wu","year":"2012","unstructured":"Wu L, Yan C, Czader M, Foreman O, Blum JS, Kapur R et al. Inhibition of PPARgamma in myeloid-lineage cells induces systemic inflammation, immunosuppression, and tumorigenesis. Blood 2012; 119: 115\u2013126.","journal-title":"Blood"},{"key":"BFonc2013217_CR35","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1158\/1535-7163.MCT-10-0570","volume":"9","author":"AK Reka","year":"2010","unstructured":"Reka AK, Kurapati H, Narala VR, Bommer G, Chen J, Standiford TJ et al. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol Cancer Ther 2010; 9: 3221\u20133232.","journal-title":"Mol Cancer Ther"},{"key":"BFonc2013217_CR36","doi-asserted-by":"publisher","first-page":"529720","DOI":"10.1155\/2008\/529720","volume":"2008","author":"H Kuniyasu","year":"2008","unstructured":"Kuniyasu H . The roles of dietary PPARgamma ligands for metastasis in colorectal cancer. PPAR Res 2008; 2008: 529720.","journal-title":"PPAR Res"},{"key":"BFonc2013217_CR37","doi-asserted-by":"publisher","first-page":"9236","DOI":"10.1158\/0008-5472.CAN-09-2067","volume":"69","author":"L Tian","year":"2009","unstructured":"Tian L, Zhou J, Casimiro MC, Liang B, Ojeifo JO, Wang M et al. Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis. Cancer Res 2009; 69: 9236\u20139244.","journal-title":"Cancer Res"},{"key":"BFonc2013217_CR38","doi-asserted-by":"publisher","first-page":"6120","DOI":"10.1038\/onc.2008.207","volume":"27","author":"H Korkaya","year":"2008","unstructured":"Korkaya H, Paulson A, Iovino F, Wicha MS . HER2 regulates the mammary stem\/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008; 27: 6120\u20136130.","journal-title":"Oncogene"},{"key":"BFonc2013217_CR39","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","volume":"1","author":"C Ginestier","year":"2007","unstructured":"Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555\u2013567.","journal-title":"Cell Stem Cell"},{"key":"BFonc2013217_CR40","doi-asserted-by":"publisher","first-page":"10715","DOI":"10.1073\/pnas.0403390101","volume":"101","author":"JA Menendez","year":"2004","unstructured":"Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R et al. Inhibition of fatty acid synthase (FAS) suppresses HER2\/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 2004; 101: 10715\u201310720.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2013217_CR41","first-page":"2983","volume":"26","author":"V Sebastiani","year":"2006","unstructured":"Sebastiani V, Botti C, Di Tondo U, Visca P, Pizzuti L, Santeusanio G et al. Tissue microarray analysis of FAS, Bcl-2, Bcl-x, ER, PgR, Hsp60, p53 and Her2-neu in breast carcinoma. Anticancer Res 2006; 26: 2983\u20132987.","journal-title":"Anticancer Res"},{"key":"BFonc2013217_CR42","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.oraloncology.2004.01.004","volume":"40","author":"SD Silva","year":"2004","unstructured":"Silva SD, Agostini M, Nishimoto IN, Coletta RD, Alves FA, Lopes MA et al. Expression of fatty acid synthase, ErbB2 and Ki-67 in head and neck squamous cell carcinoma: a clinicopathological study. Oral Oncol 2004; 40: 688\u2013696.","journal-title":"Oral Oncol"},{"key":"BFonc2013217_CR43","first-page":"132","volume":"63","author":"C Kumar-Sinha","year":"2003","unstructured":"Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM . Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 2003; 63: 132\u2013139.","journal-title":"Cancer Res"},{"key":"BFonc2013217_CR44","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1038\/onc.2011.543","volume":"31","author":"JJ Lee","year":"2012","unstructured":"Lee JJ, Drakaki A, Iliopoulos D, Struhl K . MiR-27b targets PPARgamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene 2012; 31: 3818\u20133825.","journal-title":"Oncogene"},{"key":"BFonc2013217_CR45","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1126\/science.1164097","volume":"324","author":"KE Wellen","year":"2009","unstructured":"Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB . ATP-citrate lyase links cellular metabolism to histone acetylation. Science 2009; 324: 1076\u20131080.","journal-title":"Science"},{"key":"BFonc2013217_CR46","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/01.mco.0000232894.28674.30","volume":"9","author":"JV Swinnen","year":"2006","unstructured":"Swinnen JV, Brusselmans K, Verhoeven G . Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 2006; 9: 358\u2013365.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"BFonc2013217_CR47","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.2741\/4021","volume":"17","author":"GT Robbins","year":"2012","unstructured":"Robbins GT, Nie D . PPAR gamma, bioactive lipids, and cancer progression. Front Biosci 2012; 17: 1816\u20131834.","journal-title":"Front Biosci"},{"key":"BFonc2013217_CR48","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/jnci\/92.5.418","volume":"92","author":"RG Mehta","year":"2000","unstructured":"Mehta RG, Williamson E, Patel MK, Koeffler HP . A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 2000; 92: 418\u2013423.","journal-title":"J Natl Cancer Inst"},{"key":"BFonc2013217_CR49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1023\/A:1023366117157","volume":"79","author":"H Liu","year":"2003","unstructured":"Liu H, Zang C, Fenner MH, Possinger K, Elstner E . PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res Treat 2003; 79: 63\u201374.","journal-title":"Breast Cancer Res Treat"},{"key":"BFonc2013217_CR50","doi-asserted-by":"publisher","first-page":"494161","DOI":"10.1155\/2008\/494161","volume":"2008","author":"JD Burton","year":"2008","unstructured":"Burton JD, Goldenberg DM, Blumenthal RD . Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types. PPAR Res 2008; 2008: 494161.","journal-title":"PPAR Res"},{"key":"BFonc2013217_CR51","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1002\/ijc.24683","volume":"125","author":"J Rageul","year":"2009","unstructured":"Rageul J, Mottier S, Jarry A, Shah Y, Theoleyre S, Masson D et al. KLF4-dependent, PPARgamma-induced expression of GPA33 in colon cancer cell lines. Int J Cancer 2009; 125: 2802\u20132809.","journal-title":"Int J Cancer"},{"key":"BFonc2013217_CR52","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663\u2013676.","journal-title":"Cell"},{"key":"BFonc2013217_CR53","doi-asserted-by":"publisher","first-page":"345","DOI":"10.18632\/oncotarget.457","volume":"3","author":"H Yuan","year":"2012","unstructured":"Yuan H, Kopelovich L, Yin Y, Lu J, Glazer RI . Drug-targeted inhibition of peroxisome proliferator-activated receptor-gamma enhances the chemopreventive effect of anti-estrogen therapy. Oncotarget 2012; 3: 345\u2013356.","journal-title":"Oncotarget"},{"key":"BFonc2013217_CR54","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.theriogenology.2011.12.008","volume":"77","author":"ML Sutton-McDowall","year":"2012","unstructured":"Sutton-McDowall ML, Feil D, Robker RL, Thompson JG, Dunning KR . Utilization of endogenous fatty acid stores for energy production in bovine preimplantation embryos. Theriogenology 2012; 77: 1632\u20131641.","journal-title":"Theriogenology"},{"key":"BFonc2013217_CR55","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/mrd.20494","volume":"73","author":"EM Ferguson","year":"2006","unstructured":"Ferguson EM, Leese HJ . A potential role for triglyceride as an energy source during bovine oocyte maturation and early embryo development. Mol Reprod Dev 2006; 73: 1195\u20131201.","journal-title":"Mol Reprod Dev"},{"key":"BFonc2013217_CR56","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2174\/157489212799972954","volume":"7","author":"XY Zu","year":"2012","unstructured":"Zu XY, Zhang QH, Liu JH, Cao RX, Zhong J, Yi GH et al. ATP citrate lyase inhibitors as novel cancer therapeutic agents. Recent Pat Anticancer Drug Discov 2012; 7: 154\u2013167.","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"BFonc2013217_CR57","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1046-2023(03)00032-X","volume":"30","author":"J Debnath","year":"2003","unstructured":"Debnath J, Muthuswamy SK, Brugge JS . Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30: 256\u2013268.","journal-title":"Methods"},{"key":"BFonc2013217_CR58","doi-asserted-by":"publisher","first-page":"18527","DOI":"10.1074\/jbc.M001297200","volume":"275","author":"S Hauser","year":"2000","unstructured":"Hauser S, Adelmant G, Sarraf P, Wright HM, Mueller E, Spiegelman BM . Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J Biol Chem 2000; 275: 18527\u201318533.","journal-title":"J Biol Chem"},{"key":"BFonc2013217_CR59","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.1158\/0008-5472.CAN-05-0592","volume":"65","author":"L Patrawala","year":"2005","unstructured":"Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG . Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005; 65: 6207\u20136219.","journal-title":"Cancer Res"},{"key":"BFonc2013217_CR60","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-1-61779-854-2_13","volume":"878","author":"M Christgen","year":"2012","unstructured":"Christgen M, Ballmaier M, Lehmann U, Kreipe H . Detection of putative cancer stem cells of the side population phenotype in human tumor cell cultures. Methods Mol Biol 2012; 878: 201\u2013215.","journal-title":"Methods Mol Biol"},{"key":"BFonc2013217_CR61","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/onc.2010.563","volume":"30","author":"X Wang","year":"2011","unstructured":"Wang X, Lu H, Urvalek AM, Li T, Yu L, Lamar J et al. KLF8 promotes human breast cancer cell invasion and metastasis by transcriptional activation of MMP9. Oncogene 2011; 30: 1901\u20131911.","journal-title":"Oncogene"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/onc2013217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/onc2013217","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/onc2013217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:57:22Z","timestamp":1684472242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2013217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,17]]},"references-count":61,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["BFonc2013217"],"URL":"https:\/\/doi.org\/10.1038\/onc.2013.217","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,17]]}}}